Comprehensive Strength Validated: Ranked Among China’s Top 100 Premier Pharmaceutical Suppliers

As a globally leading CDMO, Porton Pharma Solutions has earned its place among China's Top 100 Premier Pharmaceutical Suppliers through 20 years of deep industry expertise. The award evaluates candidates based on core dimensions including innovation breakthrough capabilities, business growth potential, and customer collaboration satisfaction, focusing on the core value of the pharmaceutical supply chain.

Adhering to a customer-centric approach, Porton Pharma Solutions has established a global R&D and production network spanning China, the United States, and Europe. We provide customer-centric, innovative, and reliable one-stop customized R&D and manufacturing services—covering APIs to formulations across the entire drug lifecycle from preclinical research to commercial launch—for global pharmaceutical companies, biotech firms, and research institutions. Our end-to-end CDMO solutions continue to enable the public‘s early access to good medicines, solidifying our reputation as a trusted industry partner.

ESG Performance: Ranked Among ESG Competitiveness Top 10

Enhanced Governance System

Significant Achievements in Core ESG Areas

• •Climate Targets: In March 2025, our near-term GHG reductions targets were validated by the Science Based Targets initiative (SBTi). Porton commited to reduce absolute scope 1 and 2 GHG emissions 42% by 2030 from a 2023 base year. Porton also commited to reduce absolute scope 3 GHG emissions covering purchased goods and services, fuel and energy related activities, upstream transportation and distribution, waste generated in operations, and processing of sold products 25% within the same timeframe.

• •Integrated Supply Chain and Capability Building: We have released the Supplier Code of Conduct to extend ESG requirements to our suppliers. Throughout the year, we conducted multiple ESG special programs and continuously promoted sustainable development concepts through internal communication channels to foster organizational-wide engagement.
  

Dual Recognition: Synergizing Industrial Strength and Sustainable Development

The dual honors—from being named a Top 100 Premier Supplier to ranking in the ESG Competitiveness Top 10—validate the pharmaceutical industry's evolving paradigm of "industrial hard power + ESG soft power". Porton Pharma Solutions has deeply integrated its global CDMO capabilities with sustainable development principles. We continue to strengthen our CDMO industry position through R&D investment and extensive customer coverage, while fulfilling our social responsibilities through environment protection, operational compliance, and supply chain collaboration.

Looking ahead, Porton Pharma Solutions will remain committed to its mission of "Enabling the Public’s Early Access to Good Medicines". We will focus on core business growth, increase investment in R&D and innovation, optimize customer service experiences, and deepen ESG management across all dimensions. By embedding sustainable development into our strategy and operations, we aim to contribute valuable practical experience to the high-quality development of the global pharmaceutical industry.